trial · primary record
Inebilizumab
Autoimmune Hepatitis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 180 |
| Primary completion | 2034-02-11 |
| Primary endpoint | Part 1: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs of Interest at Week 26 |
| Registry ID | NCT07598825 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:55.007Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07598825
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.